| Similar Articles |
|---|
 |
The Motley Fool
August 6, 2007
Timothy M. Otte |
Unilever Rolls Through Q2 The Dutch consumer-products company reports solid quarterly results. Investors, take note.   |
The Motley Fool
November 11, 2008
Dan Caplinger |
3 Smart Ways to Boost Your Portfolio Income Stocks could be down for a while. Make sure you're prepared. |
The Motley Fool
July 23, 2004
Rich Smith |
Sonoco Packs Profits The packaging company scores double-digit gains on almost all metrics, offering exactly what total return investors look for in a company |
The Motley Fool
March 18, 2009
Brian Orelli |
Merck Pummels Pfizer One of these acquisitions is not like the other. |
The Motley Fool
August 4, 2008
Timothy M. Otte |
Unilever Sell-Off Overdone? The consumer-products giant sees a sell-off on second-quarter results. Is the stock a good value now? |
The Motley Fool
October 17, 2006
Brian Lawler |
See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note. |
The Motley Fool
October 22, 2007
Brian Lawler |
Not Another Pfizer Pfailure As Pfizer's top execs have said before, losing patent protections on many of its top products around the same time makes for a difficult operating environment. Pfizer's third-quarter results showed just how difficult those losses were. |
The Motley Fool
August 31, 2007
Joe Magyer |
How to Stop Losing Money in Stocks If losing money causes us pain, and we don't like pain, we should try to avoid losing money, right? Four simple steps for lowering risk and boosting returns. |
The Motley Fool
November 18, 2005 |
The Dow's Components Did you know out of thousands and thousands of existing companies, just 30 make up the Dow? |
The Motley Fool
January 27, 2004
Jeff Hwang |
Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings. |
The Motley Fool
April 30, 2004
Nathan Slaughter |
P&G's Everyday Profits The consumer products giant Proctor & Gamble reports surging sales and earnings. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
December 14, 2005
Steven Mallas |
Pfizer: Of Drugs and Dividends Pfizer is raising its payout. Is it a good move for the drugmaker? Investors willing to hold for years while reinvesting dividends will most likely be rewarded along the way. |
The Motley Fool
November 5, 2007
Timothy M. Otte |
Unilever Overcomes Cost Pressures The Anglo-Dutch consumer-products giant grows profits despite cost increases. |
The Motley Fool
October 14, 2008
Brian Orelli |
Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace. |
The Motley Fool
May 8, 2006
Stephen D. Simpson |
A Little Redemption for Rock-Tenn Rock-Tenn isn't the safest idea out there, but if pricing on finished goods and natural gas stays in its favor and a deal with Procter & Gamble's Gillette business pays off, better earnings here aren't out of the question. |
The Motley Fool
October 30, 2008
Dan Caplinger |
Dump Your Losers or Double Down? If you're seeing companies in your portfolio suffer big price drops, what should you do? |
The Motley Fool
November 9, 2006
Shruti Basavaraj |
The Best Blue Chip for 2007: Johnson & Johnson If you're out looking for the best blue chip money can buy, consider Johnson & Johnson. The stock combines strong growth opportunities with stability. It's the ideal stock to build the core of your portfolio. |
The Motley Fool
August 21, 2008
Mac Greer |
Fool Video: 6 Stocks That Pay Which dividend stocks will continue to pay off for investors? This video takes a look at six contenders. |
The Motley Fool
December 19, 2006
Todd Wenning |
Don't Be Late to the Game Follow the lead of America's great companies -- investors should also be looking overseas to increase their portfolio's growth while reducing risk through diversification. |
The Motley Fool
January 31, 2005
Stephen D. Simpson |
Sealed Air Produces a Pop The packaging maker trumps Wall Street estimates and generates considerable free cash. |
The Motley Fool
May 28, 2008
Brian Lawler |
No Barrier to Deals Like This In the latest example of overlap between the pharmaceutical and consumer-health care industries, Barrier Therapeutics announces that it will package one of its lead prescription drugs with a shampoo sold by Procter & Gamble. |
The Motley Fool
August 26, 2005
Nathan Parmelee |
The Limits of Cash A strong yield is only as good as the company's ability to fund it. The market is chock-full of companies with high dividend yields, but not all of them are worthy of your investment dollars. |
The Motley Fool
November 6, 2007
Ron Vlieger |
IP Not Looking Good on Paper International Paper's latest quarter suggests that its makeover is still a work in progress. Investors, take note. |
The Motley Fool
November 28, 2005
Stephen D. Simpson |
Merck's Tighter Belt Bet Operational improvements are an expected move for Merck, but won't really improve long-term prospects. But investors must do their own due diligence to make their own calls here. |
The Motley Fool
January 23, 2009
Mike Pienciak |
These Losses Could Mean Gains Impairment charges can eventually deliver an upside. Once assets are restated at lower present values, they don't get written back up under U.S. accounting rules when the good times start to roll again. |
Inc.
February 2006
Max Chafkin |
Transforming In-Store Advertising Using existing RFID technology in a new way, companies can better test store displays. |
The Motley Fool
December 22, 2006
Todd Wenning |
Stocks That Pay You Back Supplement your income with these dividend-paying stocks: Pfizer... Merck... Procter & Gamble... Coca-Cola... |
The Motley Fool
October 20, 2008
Brian Orelli |
Foolish Forecast: Will Pfizer Flounder Through Another Quarter? Pharmaceutical giant Pfizer releases earnings tomorrow morning. Let's take a look at what the numbers might say and, more importantly, what management might be able to say to get this stock out of its drug-induced coma. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
Sealed Air Deflated Easing plastics prices would be a boon to the Cryovac food packaging specialist. Though there is a lot of potential here, especially in China, investors may want to wait for a better price before jumping in. |
